BACKGROUND: Amitraz, an insecticide used to prevent tick and mite infestation of cattle, crops and dogs, is an ␣ 2 -adrenergic receptor agonist that inhibits GnRH release and the ovulatory LH surge in rats. Noradrenalin, the physiological ligand for adrenergic receptors, inhibits progesterone production by IVF-derived granulosa cells, but the effects of amitraz are unknown. METHODS: Luteinized granulosa cells obtained from women undergoing ovarian stimulation were exposed to amitraz (1, 10, 50, 100 g/ml) for 2-72 h, and to amitraz (50 g/ml) ± hCG or the specific ␣ 2 -adrenergic receptor antagonist yohimbine, for 6 h. Cell numbers were determined by 3-(4, 5-dimethylthiazol-2 -yl)-2, 5-diphenyl tetrazolium bromide(MTT) assay and hormone production by radioimmunoassay. RESULTS: Amitraz 10 g/ml did not affect cell numbers or estrogen production, but reduced progesterone production to 58 ± 8% (p < 0.01, 24 h, n = 6) of control values. Amitraz (100 g/ml) was cytotoxic and caused a corresponding reduction in hormone production. Amitraz 50 g/ml did not affect cell numbers or estrogen production, but reduced progesterone per cell production to 82 ± 6% of control values after 6 h. This was prevented by 0.2 mmol/l yohimbine. Exposure to amitraz 50 g/ml for 6 h exposure abolished hCG-stimulated progesterone production but not estrogen production. CONCLUSIONS: Amitraz inhibited basal and hCG-stimulated progesterone but not estrogen production. The inhibitory action of amitraz and its antagonism by yohimbine suggest that ␣ 2 -adrenergic receptors are expressed by luteinized human granulosa cells.
Introduction
Amitraz is an insecticide used to prevent tick and mite infestation (Hollingworth, 1976) and is in common use around the world. Amitraz is applied to cattle (McDougall and Lewis, 1984) and sheep in dip baths at concentrations of 0.025% (Eamens et al., 2001; Mekonnen, 2001) , to dogs from collars impregnated with 0.025% amitraz, or by topical application in a bath of 0.05% amitraz (Paradis, 1999; Shaw and Foster, 2000; Elfassy et al., 2001) , to pigs in sprays containing 12.5%, and to cotton and hops (Weichel and Nauen, 2003) by spraying 20% solutions of amitraz from aeroplanes and ground sprinklers. In addition, amitraz is used to control psylla infestations of pears (Gosselin et al., 1984; Schaub et al., 2002) . Human exposure to amitraz occurs when diluting the concentrate obtained from the manufacturer, when applying the amitraz to crops or animals, and when working in amitraz-treated areas, for example pear orchards or cotton fields (US Environmental Protection Agency, 1996) . To our knowledge, there are no controlled studies describing amitraz exposure in humans.
In women, follicles within the ovaries consist of an oocyte surrounded by granulosa and theca cells, which together secrete estrogen until the mid-cycle surge of LH causes the oocyte to be ovulated and the follicular cells to differentiate into the granulosa-lutein and theca-lutein cells of the corpus luteum, which secrete both estrogen and progesterone. Agents that either change the ratio of estrogen : progesterone, or which prevent the production of steroid hormones by luteinized granulosa cells in vitro, have the potential to be reproductively toxic to women in vivo.
Amitraz is an α 2 -adrenergic receptor (α 2 -AR) agonist that adversely affects the mammalian reproductive system by binding to presynaptic α 2 -AR in the hypothalamus, thus inhibiting noradrenalin release and decreasing GnRH secretion (Altobelli et al., 2001) .
When 30 mg/kg of amitraz was administered to rats, the ovulatory LH surge was prevented (Goldman and Cooper, 1993) . Male mice that ingested 80 p.p.m. (∼0.008%) amitraz for 12 weeks prior to mating had significantly reduced sperm production and sired fewer pups than controls (Al-Thani et al., 2003) . The reproductive lowest observed effect level for amitraz was derived by exposing three generations of rats to 50 p.p.m. (∼0.005%) amitraz. This exposure resulted in reduced litter size and decreased pup survival in all three generations. Amitraz exposure of 200 p.p.m. (∼0.02%) resulted in insufficient pups to continue F 2 matings (US Environmental Protection Agency, 1996) .
Amitraz inhibited insulin but stimulated glucagon secretion in a perfused rat pancreas model (Abu-Basha et al., 1999) . Amitraz also decreased intestinal motility (Pass and Mogg, 1991) , and inhibited prostaglandin synthesis by bovine seminal vesicle microsomes (Yim et al., 1978) . Total immersion of cats in a solution of 0.025% amitraz resulted in reduced food intake and disrupted excretion, and the cats 'appeared sedated and sat quiet and immobile in their cages' (Gunaratnam et al., 1983) ; however, they had recovered completely within 3 days. The topical application of amitraz to dogs suppressed insulin release and increased plasma glucose (Hsu and Schaffer, 1988) . The topical application of amitraz (12.5%) to dermal scabies resulted in 14 children being admitted to hospital with bradycardia or tachycardia, myosis and hyperglycaemia. These symptoms were apparent 9.2 ± 5.5 min after dermal exposure (Kalyoncu et al., 2002) , suggesting that amitraz can be absorbed through the skin and can exert systemic effects via the vascular system in humans. The US Environmental Protection Agency classified amitraz as a Category II dermal toxin to humans; this is the second highest of four categories (US Environmental Protection Agency, 1996) .
The dose-dependent inhibition of noradrenalin release by amitraz in rat hypothalamic synaptosomes (Altobelli et al., 2001 ) and inhibition of insulin release by a rat β-cell line (Chen and Hsu, 1994) were reversed by yohimbine, a potent α 2 -AR antagonist (Lalchandani et al., 2002) . Yohimbine bound to α 2 -ARs with pKi values of 8-9.7, but did not antagonize α 1 or β-ARs (Lalchandani et al., 2002) .
Noradrenalin is the physiological ligand for both α-and β-ARs (Fohr et al, 1993) , and inhibited basal (Bodis, et al.,1993) and hCG-stimulated progesterone production (Fohr et al., 1993) by human IVF-derived luteinized granulosa cells in vitro. The β-AR antagonist propranolol reduced the noradrenalin-mediated inhibition of basal progesterone production (Bodis, 1993) but had no effect on hCG-stimulated progesterone production (Fohr et al., 1993) . The specific α-AR agonist phenylephrine, like noradrenalin, inhibited hCG-stimulated progesterone production, suggesting that the noradrenalin-mediated reduction of hCG-stimulated progesterone production occurred via the α-AR.
Amitraz, like noradrenalin, is an α-AR agonist, and noradrenalin reduced hCG-stimulated progesterone production by human IVF-derived luteinized granulosa cells (Fohr et al., 1993) . There are currently no data regarding the effects of amitraz on any human cell type; therefore, we aimed to determine whether amitraz has the same effects as noradrenalin on human IVF-derived luteinized granulosa cells; that is, whether amitraz will reduce hCG-stimulated progesterone production and whether the inhibitory action of amitraz will be prevented by the α 2 -AR antagonist yohimbine.
Materials and methods

Granulosa cell collection
Human granulosa cells were obtained from informed patients who consented to donate their granulosa cells in a protocol approved by the Flinders Clinical Research Ethics Committee (47/00). The patients were undergoing IVF or ICSI procedures at Reproductive Medicine, Flinders Medical Centre, South Australia. Multiple follicular development was induced after GnRH down-regulation with Synarel (Serono Laboratories, Sydney, Australia), followed by stimulation with recombinant human FSH (Gonal F75; Serono Laboratories). HCG (5000 IU; Profasi; Serono Laboratories) was administered 34-36 h before oocyte retrieval. The oocytes were removed from the follicular fluid and processed for fertilization.
The follicular aspirates from each patient were pooled, centrifuged (1500 g), for 5 minutes resuspended in culture medium, Ham's F12/ Dulbecco's Minimum Essential Medium (F12/DMEM, 1 : 1; Thermo Trace, Melbourne, Australia.) supplemented with 10% fetal calf serum (Trace Biosciences) and insulin, transferrin, selenium (ITS; Invitrogen Life Technologies, Mount Waverley, Australia). Erythrocytes were removed by centrifugation through Lymphoprep (1 g/ml; Axis Shield, Oslo, Norway). Collected granulosa cells were washed and counted using trypan blue exclusion, then distributed into 96-well plates in 100 µl of supplemented F12/DMEM and incubated in a humidified atmosphere of 5% CO 2 in air at 37°C. The granulosa cells were left to attach and luteinize for 24 h before non-attached cells and spent media were removed. Fresh media (100 µl) containing treatments were replaced every 24 h. Conditioned media were collected and frozen at −20°C for later determination of estrogen and progesterone concentrations by standard radioimmunoassay.
Preparation of treatments
Amitraz (Alltech, Sydney, Australia) in methanol (10 mg/ml) was diluted in F12/DMEM to make 1 mg/ml stock and filter-sterilized. Treatments of 1 (0.0001% w/v), 10 (0.001%), 50 (0.005%) and 100 (0.01%) µg/ml amitraz were made up by diluting an aliquot of 1 mg/ml stock in culture medium on the day of use. Appropriate methanol controls were used for each concentration of amitraz tested. For example, the 50 µg/ml amitraz controls were 1 : 200 dilutions of methanol in medium.
The α 2 -AR antagonist yohimbine (Sigma, St Louis, MO, USA) was made into a 1 mol/l solution in water. This was diluted in F12/DMEM to make a 0.01 mol/l stock and filter-sterilized. Yohimbine treatments of 2, 1, 0.2, 0.02, 0.002 mmol/l were made up in culture medium on the day of use.
HCG (Chorulon; Intervet Australia, Bendigo, Australia) 1000 IU/ml stock was made up in solvent supplied by the manufacturer. This was diluted to 10 IU/ml with F12/DMEM, and frozen in 1 ml aliquots. Working hCG preparations of 1, 0.1, 0.01 and 0.001 IU/ml were made up in F12/DMEM from the frozen aliquots on the day of use.
Treatments
Luteinized human granulosa cells (10 000 per well) in quadruplicate from a total of 29 women were exposed to 1, 10, 50 and 100 µg/ml amitraz for 2, 4, 6, 24, 48 or 72 h. The numbers of granulosa cells collected from one woman were rarely enough to examine all 24 combinations of dose, time of exposure and the controls. Each treatment was therefore examined using granulosa cells from at least three women (n = 3). When additional cells were available, experiments were repeated to a maximum of n = 6 for any one treatment. Media were replenished at 24 h intervals. Media containing steroid hormones were collected, and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assays were conducted on completion of specified exposures. Controls were the amitraz solvent methanol at the same dilution as the amitraz treatment. Each amitraz concentration was expressed as a percentage of its own methanol control for the relevant time point.
The effect of amitraz on hCG-stimulated steroidogenesis was determined by exposing luteinized granulosa cells in triplicate to 1, 10, 100, 1000 mIU/ml hCG ± 50 µg/ml amitraz for 6 h (n = 4). The control for hCG-only treatments was the manufacturer's hCG solvent diluted in F12/DMEM medium in the same manner as the 1000 mIU hCG treatment. This gave the same unstimulated basal progesterone and estrogen concentrations as medium alone. hCG-stimulated steroid hormone production was expressed as a percentage of the solvent control, such that identical steroid hormone production by both the hCG-treated and the control-treated cells would result in a value of 100%. Amitraz + hCG steroid hormone production was expressed as a percentage of the combined methanol + hCG solvent control.
The mechanism of action of amitraz was determined by exposing luteinized granulosa cells to 50 µg/ml amitraz for 6 h, ± 0.002, 0.02 0.2, mmol/l yohimbine (n = 5). The steroid hormone production per cell for each concentration of yohimbine was set as 100, and the corresponding amitraz + yohimbine treatment was expressed as a percentage of the yohimbine-only control.
MTT cell number assay
Metabolically active cells convert yellow, water-soluble MTT (Sigma) to the purple, water-insoluble end-product, formazan. The amount of formazan formed is proportional to the number of metabolically active cells (Mossman, 1983) . Luteinized granulosa cells were incubated with 0.5 mg/ml MTT for 18 h, formazan crystals were extracted and dissolved by incubation with 20% sodium dodecyl sulphate in 0.02 mmol/l HCl for 1 h, and absorbance was measured at 570 nm in a Bio-Rad Plate Reader. Regents Park, NSW, Australia MTT standard curves were constructed by plating out granulosa cells at concentrations of 40 000 to 156 cells/well. Six replicates of the standard curve were constructed for the cells from each woman, and the numbers of granulosa cells remaining in wells after specified treatments were determined by comparison with the standard curve from the same woman. In some cases, the concentration of steroid hormones in a well was divided by the number of cells in the same well to give an approximation of the amount of hormone produced per cell. The mean of replicate hormone values per cell was calculated for each woman.
Estrogen and progesterone radioimmunoassay
Radioimmunoassay using human progesterone standards, rabbit antiprogesterone antiserum and 125 I-radiolabelled progesterone (all from ICN Pharmaceuticals, Costa Mesa, CA, USA) were used to quantify progesterone in tissue culture media. The interassay coefficient of variation was 14%, and the sensitivity of the assay was 0.2 ng/ml.
Similarly, estradiol (E 2 ) in tissue culture samples was quantified by radioimmunoassay using human E 2 standard (DSL, Webster, Texas, USA), rabbit anti-E 2 -17β antiserum and 125 I-radiolabelled E 2 (ICN Pharmaceuticals). The cross-reactivity of the antiserum showed 100% cross-reactivity with E 2 -17β and 6.5% or less with other steroids tested. The interassay coefficient of variation was 12% and the sensitivity of assay was 20 pg/ml.
Sheep anti rabbit serum (Silenus, Boronia, Australia) was used as a second antibody in both assays to separate bound and free fractions.
Statistical analysis
One-way analysis of variance was conducted on cell numbers, progesterone or estrogen values, and followed by Fisher's post hoc test. HCG data, expressed as percentages of controls, were subjected to χ 2 analysis, and a paired t-test was applied to data on progesterone per cell obtained after yohimbine treatment. Significance was assigned at P < 0.05. The data are presented as a percentage of control values in figures because of the amount of variability in basal steroidogenesis between patients. Points in figures represent the mean ± SEM of the percentage of controls from different patients (n refers to patient numbers).
Results
Amitraz was not cytotoxic to human luteinized granulosa cells at concentrations of 1, 10 or 50 µg/ml for exposures of 2-72 h.
The highest concentration of amitraz tested, 100 µg/ml, caused significant cell death after exposures of 24, 48 and 72 h (Table 1) . Amitraz tended to decrease the amount of progesterone produced by each granulosa cell during exposure periods of 2, 4 and 6 h (Figure 1 ), but high biological variation (Table 2) obscured the results. Progesterone per cell production in control wells was 0.00766 ± 0.00497 ng/ml (mean ± SD, Table 2 ) after 2 h, which suggests a production rate of 0.003 ng/ml per cell per hour. The hourly production rates were also 0.003 ng/ml per cell for both the 4 and 6 h control incubation times, suggesting that progesterone production per cell was linear over the 6 h range examined. Table I . Effects of amitraz on luteinized granulosa cell viability Luteinized human granulosa cells were exposed to amitraz (1, 10, 50 and 100 µg/ml) for 2, 4, 6, 24, 48 and 72 h and the numbers of viable cells remaining at the end of the exposure periods were determined in a 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) assay. Calculated by expressing the viable cell number per well after amitraz treatment as a percentage of the methanol control; mean ± SD of n percentages. Cell numbers (treated versus controls) were subjected to ANOVA. *P < 0.05; **P < 0.01. Exposures from 2 to 72 h had no significant effect upon cell number (Table 1) , progesterone (Figures 1 and 3 ) or estrogen production ( Figure 2 ) by human luteinized granulosa cells.
Effect of 10 µg/ml (0.001% w/v) amitraz on human luteinized granulosa cells
Exposure from 2 to 72 h did not significantly reduce cell numbers (Table I) or estrogen production (Figure 2 ). Two hours of exposure to 10 µg/ml amitraz did not affect progesterone production, but 4 and 6 h of exposure tended to reduce progesterone production per cell to 82 ± 4% (mean ± SEM, n = 6) and 77 ± 7% (mean ± SEM, n = 4) of methanol control values respectively (Figure 1 ). Longer exposures to 10 µg/ml amitraz significantly decreased progesterone production to 58 ± 8% (P < 0.01, n = 6) of control values after 24 h exposure, to 58 ± 3% (P < 0.05, n = 5) after 48 h exposure (data not shown) and to 63 ± 8% (P < 0.05, n = 3) after 72 h exposure (Figure 3) .
Effect of 50 µg/ml amitraz on human luteinized granulosa cells
Exposure for 6 h did not affect cell numbers, which were 101 ± 10% of methanol control values (mean ± SD, n = 10, Table I ), or estrogen production, which was 97 ± 14% of control values (mean ± SEM, n = 4). Progesterone production (mean ± SEM) by luteinized granulosa cells exposed to 50 µg/ml amitraz was 89 ± 21% of methanol control values for 2 h of exposure (n = 5), 85 ± 8% for 4 h of exposure (n = 6) and 82 ± 6% for 6 h of exposure (n = 4). The 50 µg/ml dose of amitraz inhibited basal progesterone production by approximately 15% at exposures of 2-6 h. There was no significant difference between the 50 µg/ml amitraz methanol control and F12/DMEM media; cell numbers were 13209 ± 6088 and 13968 ± 5941, and progesterone production was 148 ± 4 and 169 ± 63 ng/ml respectively (mean ± SD, n = 6).
Effect of 100 µg/ml (0.01% w/v) amitraz on human luteinized granulosa cells
Two hours of exposure to 100 µg/ml amitraz had no effect on progesterone production by granulosa cells obtained from four out of five women, but exposures of 4 and 6 h reduced progesterone per cell production to 64.8 ± 13.5% and 60.47 ± 31.8% (mean ± SD) of time-matched controls respectively (Table II and Figure 1 ). Significant cell death caused by high amitraz concentrations (100 µg/ ml; Table I ) resulted in reduced estrogen (P < 0.01) and progesterone (P < 0.05 and P < 0.01) production for the corresponding treatments (Figures 2 and 3 ) when compared with controls.
Effect of amitraz on HCG-stimulated hormone production by human luteinized granulosa cells
Exposure to HCG for 6 h stimulated both estrogen and progesterone production in a dose-dependent fashion (Figures 4 and 5) . A paired t-test on 0 HCG vs 1000 HCG estrogen concentrations was significantly different (P< 0.001, n = 4)) HCG significantly stimulated estrogen production after a 6 h exposure. Interestingly, exposure to 50 µg/ml amitraz for 6 h did not affect HCG-stimulated Figure 1 . Effect of short amitraz exposures on progesterone production per cell. Human luteinized granulosa cells were exposed to 1, 10 and 100 µg/ml amitraz for 2, 4 and 6 h. Progesterone (ng/ml) secreted into culture media was measured by radioimmunoassay. Cell numbers were determined by the MTT assay. Progesterone production per cell was determined, subjected to analysis of variance, then expressed as a percentage (mean ± SEM) of the relevant control. Table II . Effects of amitraz on progesterone production by luteinized granulosa cells
Luteinized human granulosa cells were exposed to amitraz (100 µg/ml) for 2, 4 and 6 h. Progesterone per well (ng/ml) was divided by the number of cells in that well, and the mean of four replicate wells obtained for each woman. Control values were obtained from cells cultured with standard culture medium containing methanol at the same dilution as cells in the amitraz-treated wells. The effect of amitraz on progesterone production per cell was expressed as a percentage of the control for each woman. There were no significant differences between treatments at any time-point using ANOVA. estrogen production (Figure 4 ), but did prevent HCG stimulation of progesterone production in the presence of all concentrations of HCG ( Figure 5 ). In addition, the 50 µg/ml dose of amitraz further reduced HCG-stimulated progesterone production to levels that were approximately 15% lower than basal, unstimulated control concentrations.
Effect of yohimbine on amitraz-mediated inhibition of progesterone production
The α 2 -AR antagonist, yohimbine, had no effect on progesterone production. Progesterone per cell values were 91 ± 5, 99.7 ± 14 and 116 ± 16% (mean ± SD) of control progesterone per cell values after yohimbine treatments of 0.002, 0.02 and 0.2 mmol/l respectively. Exposure to 50 µg/ml amitraz for 6 h caused progesterone production per cell to be 0.0126 ± 0.004 ng/ml (mean ± SEM, n = 5), whereas exposure to 50 µg/ml amitraz + 0.2 mmol/l yohimbine resulted in a significant increase (P < 0.01) in progesterone production per cell to 0.0225 ± 0.007 ng/ml; 0.2 mmol/l yohimbine prevented amitraz-mediated inhibition of progesterone production. Progesterone production per cell after 6 h exposure to 0.2 mmol/l yohimbine was 0.0225 ± 0.007 ng/ml, exactly the same as the amitraz + yohimbine treatment although the composite data Figure 2 . Effect of amitraz on estrogen production. Human luteinized granulosa cells were exposed to 1 (n = 3), 10 (24 h, n = 6; 72 h, n = 3) and 100 µg/ml (24 h, n = 4; 72 h, n = 3) amitraz for 24 and 72 h. Estrogen secreted into the culture medium was measured by radioimmunoassay and subjected to ANOVA. Estrogen (pg/ml) is shown as a percentage (mean ± SEM) of the relevant control. **P < 0.01. Amitraz (ug/ml) pg/ml Estradiol (% of Control)
24hr (n=3) 72hr (n=3) ** Figure 3 . Effect of long amitraz exposures on progesterone production. Human luteinized granulosa cells were exposed to 1 (n = 3), 10 (24 h, n = 6; 72 h, n = 3) and 100 µg/ml (24 h, n = 4 72 h, n = 3) amitraz for 24 and 72 h. Progesterone secreted into the culture medium was measured by radioimmunoassay and subjected to ANOVA. Progesterone (ng/ml) is shown as a percentage (mean ± SEM) of the relevant control.*P < 0.05; **P < 0.01. Human luteinized granulosa cells were exposed to 1, 10, 100 or 1000 mIU HCG, or to one of these HCG doses and 50 µg/ml amitraz, for 6 h. HCG treatments are expressed as a percentage of the HCG solvent control; HCG + amitraz treatments are expressed as a percentage of the HCG solvent + methanol control. All percentages (for four women) are expressed as mean ± SEM. Figure 5 . Effect of amitraz on HCG-stimulated progesterone production. Human luteinized granulosa cells were exposed to 1, 10, 100 or 1000 mIU HCG, or to one of these HCG doses + 50 µg/ml amitraz, for 6 h. HCG treatments are expressed as a percentage of the HCG solvent control; HCG + amitraz treatments expressed as a percentage of the HCG solvent + methanol control. All percentages (for four women) are expressed as mean ± SEM. Percentages for amitraz + HCG are compared with percentages for the same dose of HCG in a χ 2 analysis. *P < 0.05; **P < 0.01. 
Log hCG (mIU) Progesterone (Percent of Basal Production)
Control 50ug/ml Amitraz from individual women were not identical. Progesterone per cell from each amitraz + yohimbine treatment was expressed as a percentage of the corresponding yohimbine treatment from the same woman. The 0.2 mmol/l yohimbine + amitraz treatment was 99.4 ± 2% (mean ± SD, n = 5; Figure 6 ) of the yohimbine treatment. Reduction in yohimbine concentration resulted in decreased progesterone production per cell in the presence of 50 µg/ml amitraz ( Figure 6 ).
Discussion
Exposure to 1 µg/ml (0.0001%) amitraz did not cause cytotoxicity or reduce steroidogenesis in human luteinized granulosa cells treated for periods of 2-72 h. The higher concentration of 10 µg/ml (0.001%) amitraz similarly did not cause cell death, but was found to inhibit progesterone production whilst having no effect upon estrogen production. Amitraz decreased the amount of progesterone produced by each cell after a 4 h exposure; the reduction in progesterone concentration was not caused by decreased cell viability. 24h exposure to 100 µg/ml (0.01%) amitraz was cytotoxic, but still had the same effect on steroidogenesis as that noted at lower doses and exposures; progesterone production was significantly reduced. Exposure to the highest dose of amitraz for 72 h also caused cell death, but at this exposure the reduction in cell number was accompanied by reduced production of both estrogen and progesterone.
How could progesterone but not estrogen synthesis be differentially inhibited? Cholesterol is converted to pregnenolone by the cytochrome P450 side-chain cleavage enzyme, and pregnenolone is converted to progesterone by 3β-hydroxysteroid dehydrogenase (3βHSD). Progesterone can be a precursor for estrogen synthesis, but if this were the case, the amitrazmediated inhibition of progesterone production would reduce the amount of precursor available for estrogen synthesis with a consequent reduction in estrogen production. Pregnenolone is also a precursor for estrogen synthesis. The amount of pregnenolone converted to progesterone is dependent upon the activity of only one enzyme; 3βHSD. Therefore we speculate that amitraz reduces progesterone, but not estrogen synthesis, by inhibiting 3βHSD activity. Another possibility is that amitraz increased the metabolism of progesterone. If this were the case, the doses of amitraz examined were insufficient to cause complete metabolism of all the progesterone that was produced.
The magnitude of HCG-stimulated steroidogenesis was consistent with previous reports (Endo et al., 1993) . Amitraz abolished the stimulatory effects of HCG on progesterone production, but had no effect on HCG-stimulated estrogen production, lending support to the speculation that amitraz blocked the action of HCG by acting on 3βHSD. It was found that 50 µg/ml amitraz caused basal progesterone production to be reduced by approximately 15%, and this could be attributed to a 15% increase in progesterone metabolism. However, if this were the case, it would be expected that HCG-stimulated progesterone production would only be reduced by 15%, thus giving rise to an attenuated HCG response. Since HCG stimulation was abolished, and not just reduced, it was concluded that amitraz did not cause metabolism of progesterone and instead reduced progesterone production by another mechanism.
The levels of 3βHSD mRNA in primate corpora lutea are highest during the early luteal phase, and decrease as the luteal phase proceeds (Fairchild Benyo et al., 1993; Duncan et al., 1999) . In primates, administration of either of the luteolytic agents prostaglandin F 2 α or GnRH antagonist caused a decrease in 3βHSD mRNA and protein within 24 h and so prevented LH-stimulated steroidogenesis (Fairchild Benyo et al., 1993; Duncan et al., 1998) . In the present study, amitraz abolished HCG-stimulated progesterone, but not estrogen production within 6 h, which suggests that amitraz acted distally to the production of pregnenolone, and blocked HCG stimulation by down-regulating 3βHSD. It is possible that amitraz may activate existing physiological luteolytic mechanisms that down-regulate 3βHSD.
Yohimbine is an α 2 -AR antagonist (Lalchandani et al., 2002) that prevented the action of amitraz in other systems (Altobelli et al., 2001) . In this study, yohimbine prevented amitraz-mediated inhibition of progesterone production in a dose-dependent fashion, suggesting firstly that human luteinized granulosa cells express α 2 -ARs, and secondly that α 2 -ARs mediated the mechanism of action of amitraz. A 6 h exposure to the α-AR agonist phenolephrine (PHE) did not affect basal progesterone production, but did inhibit HCG-stimulated progesterone production (Fohr et al., 1993) . These data are consistent with those in this report. Amitraz is an α-AR agonist which did not cause a statistically significant reduction in basal progesterone production during a 6 h exposure, but did cause a significant inhibition of HCG-stimulated progesterone production in the same time period. In addition, PHE alone had no effect on cytosolic free Ca 2+ levels, but the combination of HCG and PHE elevated Ca 2+ (Fohr et al., 1993) . It is not known if a 24 h exposure to PHE alone would have inhibited progesterone production in a manner similar to amitraz, or if Figure 6 . Effect of yohimbine on amitraz-mediated inhibition of progesterone production. Human luteinized granulosa cells were exposed to 50 µg/ml amitraz ± 0.002, 0.02 or 0.2 mmol/l yohimbine for 6 h. Progesterone (ng/ml) secreted into the culture medium was measured by radioimmunoassay. Cell numbers were determined by MTT assay. Progesterone production per cell during amitraz + yohimbine treatment was expressed as a percentage of yohimbine-only controls; 100% means that yohimbine completely blocked the effects of amitraz. All percentages (five women) are expressed as mean ± SEM. the combination of amitraz and HCG would elevate Ca 2+ in the same manner as PHE + HCG. The effect of elevated intracellular Ca 2+ on 3βHSD activity is also unknown. Both amitraz and PHE bind α-ARs. Noradrenalin is a physiological ligand for both α and β-ARs, but the β-AR agonist isoproteronol had no effect on HCG-stimulated progesterone production or cytosolic Ca 2+ levels in human luteinized granulosa cells, suggesting that only the α-AR mediates inhibition of progesterone production (Fohr et al., 1993) . Noradrenalin slightly reduced progesterone production by four human corpora lutea in vitro (Casper and Cotterell, 1984) , which was consistent with the finding that amitraz, a noradrenalin analogue, inhibited progesterone production by human granulosa-lutein cells, one of the components of the human corpus luteum.
The amitraz in cattle dips and dog collars is commonly used at concentrations of 0.025%. The dermal absorption of amitraz by humans can cause hyperglycaemia and have other physiological effects (Kalyoncu et al., 2002) , but blood concentrations of amitraz have not been correlated to the area or duration of dermal exposure. Metabolism and clearance rates of amitraz in humans are not clear, and it is not known if amitraz in the peripheral blood system would cross the basement membrane of ovarian follicles and gain access to granulosa cells. However, the corpus luteum is highly vascularized, and it is possible that amitraz in circulating blood could gain access to α 2 -ARs expressed by granulosa-lutein cells in vivo.
If amitraz was found to also reduce progesterone production by women in vivo, would there be any impact on fertility? The amount of progesterone that a woman synthesizes can be represented by a 'progesterone index' (PI), which can be determined by calculating the mean of four progesterone measurements taken daily during the early luteal phase. It was found that the PI remains constant between cycles for any one woman, and that women with PI lower than 30 nmol/l have difficulty becoming pregnant (Lenton and Landgren, 1985; Sallam et al., 1999) . If a woman already has a low PI, then exposure to amitraz has the potential to exacerbate the situation and decrease progesterone production to levels associated with infertility. Additionally, this study found that a 6 h exposure to 50 µg/ml (0.005%) amitraz completely abolished the embryonic HCG signal. Exposure to amitraz that results in blood concentrations of >50 µg/ml for 6 h therefore has the potential to prevent establishment of pregnancy or to cause miscarriage. However, the relative importance of amitraz's inhibition of luteal progesterone production with respect to overall fertility has yet to be elucidated, although amitraz is also reproductively toxic in the hypothalamus (Altobelli et al., 2001) , where its action ultimately prevents ovulation in females (Goldman and Cooper, 1993) , and probably reduces sperm production in males (Al-Thani et al., 2003) . This is the first report of amitraz having an effect on human cells. Since amitraz activated α 2 -ARs expressed by human luteinized granulosa cells, amitraz may also bind to hypothalamic α 2 -ARs, with the potential to prevent the ovulatory LH surge in women. Amitraz can be absorbed through the skin and have systemic effects in humans (Kalyoncu et al., 2002) . Taken together, these data suggest that amitraz has the potential to be a reproductive toxin in humans.
In conclusion, amitraz bound to α 2 -ARs expressed by human luteinized granulosa cells and inhibited basal progesterone, but not estrogen, production. Amitraz also inhibited HCGstimulated progesterone production, but not estrogen production. This differential inhibition of progesterone production but not estrogen production suggests that amitraz may act on the steroidogenic enzyme 3βHSD. The lowest dose of amitraz tested, 1 µg/ml (0.0001%), had no effect when cells were exposed for 2-72 h, but 10 µg/ml (0.001%) inhibited progesterone production and 100 µg/ml (0.01%) amitraz killed cells after a 24 h exposure. The reproductive toxicity of amitraz to mammals has already been established (Goldman and Cooper, 1993) , but this is the first study to show that amitraz inhibits the production of the steroid hormone progesterone, directly, and that amitraz is toxic to human reproductive cells in an in vitro model system.
